*  Patent US7981863 - Treatment of Parkinson's disease with PDGF - Google Patents
... invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment ... heparin) the VEGF receptor antagonists were also able to block the effect of the exogenously applied VEGF (. FIG. 28. , right ... and the limitations inherent in the art of compounding such an active compound for the treatment of individuals. ... VEGF-165 also binds to heparin and is the most abundant form. VEGF-121, the only form that does not bind to heparin, appears to ...
  http://www.google.com/patents/US7981863?dq=7,134,016
*  Patente US20040258726 - Methods and materials for nanocrystalline surface coatings and attachment of ... - Google Patentes
Alternatively, the nanofiber encapsulated cells or compound in the coating used in embodiments of the invention treatment ... These compositions may include heparin, coumarin, aspirin, fish oils, calcium antagonists, steroids, and prostacyclin. Such ... Surface treatment for an implant surface. US9198742. 27 Ago 2014. 1 Dic 2015. Biomet 3I, Llc. Implant surface with increased ... Treatment of the pLys-OCP with a biological enzyme, such as pronase, shows by SEM and energy dispersive x-ray spectroscopy (EDS ...
  http://www.google.es/patents/US20040258726
*  Direct Xa inhibitor - Wikipedia
... promise for these compounds as substitutes for the currently administered vitamin K antagonists or low molecular weight heparin ... against low-molecular-weight heparin for treatment and secondary prevention of venous thromboembolism or for initial treatment ... domain of native fXa but retain the ability of native fXa to bind direct fXa inhibitors as well as low molecular weight heparin ...
  https://en.wikipedia.org/wiki/Direct_Xa_inhibitor
*  Patent US5971951 - Aerosol extrusion mechanism - Google Patents
... tachykinin antagonists, bradykinin antagonists, endothelin antagonists, heparin furosemide, anti-adhesion molecules, cytokine ... The compound can be directed to a particular area of the lung which needs treatment by adjusting the aerosol particle size. By ... The term "respiratory drug" as used herein means any pharmaceutically effective compound used in the treatment of any ... The desiccator material can be any compound which absorbs water vapor from air. For example, it may be a compound selected from ...
  http://www.google.ca/patents/US5971951
*  Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) - Full Text View - ClinicalTrials.gov
... vitamin K antagonists (warfarin) in the 3 days preceding study drug infusions; unfractionated heparin or low molecular weight ... Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS) medications, ... Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP). This study has been completed. ... We have designed a randomized, double blind, placebo controlled pilot trial of rituximab for the treatment of non- ...
  https://clinicaltrials.gov/ct2/show/NCT00372892
*  PF4 antagonists as therapeutics for heparin induced thrombocytopenia and thrombos | SBIR.gov
... a serious complication of heparin therapy for which there is currently nospecific treatment. Heparin is a naturally-occurring ... The goal for phase 1 of this project is to identify a diverse set of lead compounds with favorable pharmacological properties ... PF4 antagonists as therapeutics for heparin induced thrombocytopenia and thrombos. Printer-friendly version ... As a large number of hospitalized patients are exposed to heparin, HITT is a major cause of treatment-induced morbidity and ...
  https://www.sbir.gov/sbirsearch/detail/370137
*  LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME - Free Online Library
... aspirin and another specific antagonist of the IIb~IIIa receptor. TP-9201 was the only compound to keep the blood vessel open ... Existing commercial treatments for prevention of blood clotting are known to increase the risk of bleeding. The findings on TP- ... demonstrated the superiority of TP-9201 in preventing occlusion in a thrombogenic blood vessel when compared to heparin, ... The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ...
  https://www.thefreelibrary.com/LEADING+RESEARCHERS+REPORT+THAT+TP-9201+PREVENTS+BLOOD+CLOTTING+...-a012893054
*  Most recent papers with the keyword long term acute care | Read by QxMD
For decades, low molecular weight heparin (LMWH), fondaparinux and Vitamin K antagonists (VKAs) have been the standard of ... Hematopoietic stem cell transplantation has become a well-established treatment for hematologic disorders including acute ... that specifically inhibit either thrombin or factor Xa have resolved many of these drawbacks because these new compounds ... What have we learned from real-world NOAC studies in venous thromboembolism treatment? ...
  https://www.readbyqxmd.com/keyword/28919
*  PolyMedix Announces Positive Phase I Clinical Data with PMX-30063 Novel Antibiotic Drug Candidate - Drugs.com MedNews
... reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is ... The first intended clinical indication for PMX-30063 is as a pan-Staph agent, for the broad treatment of Staph infections, not ... PolyMedix's compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity ... The Company's antibiotic compounds, including PMX-30063 - small molecule mimetics of human host-defense proteins - have a ...
  https://www.drugs.com/clinical_trials/polymedix-announces-positive-phase-clinical-data-pmx-30063-novel-antibiotic-candidate-6491.html
*  Heparin and other polyanions uncouple α1-adrenoceptors from G-proteins | Biochemical Journal
This action of heparin severely limits its utility as a selective antagonist of the Ins(1,4,5)P3 receptor in intact cells. ... After alkaline treatment of the membranes, previously reported to cause G-protein removal, binding of agonists was insensitive ... Several polyanionic compounds antagonize the interaction between receptors and the G-proteins that regulate adenylate cyclase ... Heparin and other polyanions uncouple α1-adrenoceptors from G-proteins. L L T Dasso, C W Taylor ...
  http://www.biochemj.org/content/280/3/791
*  Naturopathic Prevention and Treatment of Swine Flu H1N1
It may interfere with H-2 antagonists, proton pump inhibitors, antihypertensives, barbiturates and sedatives, and heparin.[31 ... Licorice compounds are showing promise in the treatment of HIV related diseases and chronic Hepatitis B (40% of patients will ... Interferon is being experimentally tested in treatment of different forms of cancer; however treatment with externally ... Naturopathic Prevention and Treatment of Swine Flu H1N1 The 2009 swine flu outbreak is the spread of a new strain of H1N1 ...
  https://www.carahealth.com/health-conditions-a-to-z/immune-system/swine-flu-h1n1-pandemic/268-swine-flu-h1n1-natural-prevention.html?lang=en
*  Factor Xa based anticoagulant compositions - Patent # 5120537 - PatentGenius
Bleeding is a common complication of vitamin K antagonist treatment and, as with heparin, the effective dose is hard to monitor ... Further these small compounds are cleared rapidly form the blood stream and the monitoring of a maintenance doseis complex.. ... Heparin and vitamin K antagonists such as Coumarin and aspirin are the most widely used anticoagulants. Heparin works in ... Heparin treatment is not effective in all cases since antithrombin III is often at low levels in severe shock and other ...
  http://www.patentgenius.com/patent/5120537.html
*  US5731326A - PDGF antagonists II - Google Patents
The non-peptide PDGF antagonists may optionally be administered coordinately with heparin, whereby the coordinately ... The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl ... administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia. ... Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell ...
  https://patents.google.com/patent/US5731326
*  Patent US8128687 - Drug-eluting stent with filament strands - Google Patents
... structure in a spaced apart orientation and loaded with at least one therapeutic drug for the release thereof at a treatment ... antagonists, fish oil (omega 3-fatty acid), histamine antagonists, Lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol ... The treatment of diseases using the above therapeutic agents is known in the art. The calculation of dosages, dosage rates and ... Metallization of selectively implanted AIII -BV compound semiconductors. US4417576. 25 Feb 1982. 29 Nov 1983. Baran Ostap E. ...
  http://www.google.co.uk/patents/US8128687
*  Vpt 311 General and Systemic Veterinary Pharamacology Tanuvas Lect Notes | Pharmacology | Cell Membrane
HEPARIN ANTAGONIST Protamine sulphate is a strongly basic low molecular weight protein obtained from the sperm of certain fish ... began to appear and the era of antimicrobial chemotherapy began with the discovery of arsenical compounds for the treatment of ... HeparinHeparin is used both as in vitro and in vivo anticoagulant. Heparin is used parenterally as an anticoagulant. • It ... Eg: acetylcholine and its antagonist atropine. • Noncompetitive antagonist: The antagonist is not chemically related to the ...
  https://www.scribd.com/doc/105615542/Vpt-311-General-and-Systemic-Veterinary-Pharamacology-Tanuvas-Lect-Notes
*  Patent US20040098106 - Intraluminal prostheses and carbon dioxide-assisted methods of impregnating ... - Google Patents
Examples of antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins ... antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol ... Surface treatment method for stent coating. US6139511 *. 29 Jun 1998. 31 Oct 2000. Advanced Cardiovascular Systems, Inc.. ... and it's analogs and all compounds in the TAXOL (Bristol-Myers Squibb Co., Stamford, Conn.) family of pharmaceuticals, ...
  http://www.google.com.au/patents/US20040098106?cl=en
*  Patent US8617094 - Fluid infusion methods for glaucoma treatment - Google Patent
... heparin, therapeutic drugs (such as beta-adrenergic antagonists, TGF-beta, and other anti-glaucoma drugs, or antibiotics), and ... a beta-adrenergic antagonist, a TGF-beta compound, and/or an antibiotic. ... Combined treatment for cataract and glaucoma treatment. US20030097117 *. 11 feb 2002. 22 maj 2003. Buono Lawrence M.. Spray ... Method and apparatus for treatment of glaucoma. US20020072673. 11 dec 2000. 13 jun 2002. Yamamoto Ronald K.. Treatment of ...
  http://www.google.se/patents/US8617094
*  AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke | Stroke
Other drug treatments such as aspirin and heparin were allowed.. All patients gave their written informed consent to ... Several AMPA antagonists have been developed as neuroprotective compounds and have entered clinical development. None of these ... In the final model, baseline NIHSS score and treatment group were included as independent variables, and time of treatment and ... 4 AMPA antagonists also hold promise as neuroprotective compounds in acute ischemic stroke, but thus far they have not reached ...
  http://stroke.ahajournals.org/content/33/12/2813
*  Patent US7270675 - Method of forming a tubular membrane on a structural frame - Google Patents
... heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, ... However, these treatments tend to be somewhat expensive and are not curative. Other procedures involve surgical intervention to ... gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives: (cyclosporine, tacrolimus (FK-506), ... 11b/111a inhibitors and vitronectin receptor antagonists; antiproliferative/antimitotic alkylating agents such as nitrogen ...
  http://www.google.com/patents/US7270675?dq=6,654,957
*  Patente US20140067038 - Devices and systems for retaining a medical device at a treatment site - Google Patentes
... heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, ... gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives: (cyclosporine, tacrolimus (FK-506), ... IIb/IIIa inhibitors and vitronectin receptor antagonists; anti-proliferative/antimitotic alkylating agents such as nitrogen ... Tines 520 may also engage the anatomy at a treatment site to retain medical device 560 at the treatment site. ...
  http://www.google.es/patents/US20140067038
*  Patent US20070276476 - Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings ... - Google Patents
Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device ... These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of ... Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the ... Thus, heparin may be effectively utilized in conjunction with rapamycin in the treatment of vascular disease. Essentially, the ...
  http://www.google.com.au/patents/US20070276476
*  Coatings for implantable medical devices - Patent # 8563025 - PatentGenius
... compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit ... antagonists,fish oil (.omega.-3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a ... The substance can be for inhibiting themigration and/or proliferation of smooth muscle cells or for the treatment of restenosis ... Albumin (also known as albumen or the egg white protein) can be used as the protein, andheparin, heparin derivatives, including ...
  http://www.patentgenius.com/patent/8563025.html
*  Ryanodine receptor subtype 2 encodes Ca2+ oscillations activated by acetylcholine via the M2 muscarinic receptor/cADP-ribose...
... after rapamycin treatment, confirmed that both compounds interacted with the ryanodine receptor subtype 2. Our findings show ... In the presence of heparin, application of 10 nM 4DAMP was unable to modify the heparin-resistant Ca2+ response whereas 10 μM ... Ca2+ oscillations were selectively inhibited by methoctramine (a M2 muscarinic receptor antagonist). The M2 muscarinic receptor ... Compiled data from permeabilized cells showing the effect of heparin (1 mg/ml), and heparin in presence of 10 μM methoctramine ...
  http://jcs.biologists.org/content/118/10/2261
*  Patente US20060200113 - Liquid jet for glaucoma treatment - Google Patentes
Methods of treating glaucoma are described including treatment of an eye with a liquid jet. The liquid jet can be generated by ... heparin, therapeutic drugs (such as beta-adrenergic antagonists, TGF-beta, and other anti-glaucoma drugs, or antibiotics), and ... a beta-adrenergic antagonist, a TGF-beta compound, and/or an antibiotic. ... Glaucoma treatment device. US8852136. 8 Dic 2011. 7 Oct 2014. Aquesys, Inc.. Methods for placing a shunt into the intra-scleral ...
  http://www.google.es/patents/US20060200113
*  Patente US9295756 - Methods for inducing immune tolerance to organ transplants - Google Patentes
IL2R antagonist, leucotriene antagonists), and/or factors that modify the coagulation cascade (e.g., aspirin, heparin-binding ... Such compounds include, but are not limited to, one or more growth factors (e.g., VEGF, DKK-I, FGF, BMP-I, BMP-4, SDF-I, IGF, ... Preparation of a Tissue or Organ for Pre-Treatment. A heart-beating mammal donor is systemically heparinized in order to ... In one embodiment, one or more compounds can be applied to the protective solution, for example, to preserve the treated tissue ...
  http://www.google.es/patents/US9295756